Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,693 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of paracentesis on the survival of patients with terminal cancer and ascites: a propensity score-weighted analysis of the East Asian Collaborative Cross-cultural Study to Elucidate the Dying Process.
Masuda K, Ishiki H, Yokomichi N, Yamaguchi T, Ito T, Takatsu H, Amano K, Hiramoto S, Yamauchi T, Kawaguchi T, Mori M, Matsuda Y, Yamaguchi T. Masuda K, et al. Support Care Cancer. 2022 Jul;30(7):6233-6241. doi: 10.1007/s00520-022-07057-8. Epub 2022 Apr 21. Support Care Cancer. 2022. PMID: 35449369
Abnormal air-righting reflex in striatal rats.
Masuda K, Yamaguchi T. Masuda K, et al. Jpn J Physiol. 2000 Feb;50(1):163-6. doi: 10.2170/jjphysiol.50.163. Jpn J Physiol. 2000. PMID: 10866710 Free article.
Optimal Paracentesis Volume for Terminally Ill Cancer Patients With Ascites.
Ito T, Yokomichi N, Ishiki H, Kawaguchi T, Masuda K, Tsukuura H, Funaki H, Suzuki K, Oya K, Nakagawa J, Mori M, Yamaguchi T. Ito T, et al. Among authors: masuda k. J Pain Symptom Manage. 2021 Nov;62(5):968-977. doi: 10.1016/j.jpainsymman.2021.04.010. Epub 2021 Apr 29. J Pain Symptom Manage. 2021. PMID: 33933616
Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.
Tamura K, Okuma Y, Nomura S, Fukuda A, Masuda K, Matsumoto Y, Shinno Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Ohe Y. Tamura K, et al. Among authors: masuda k. J Cancer Res Clin Oncol. 2024 Apr 26;150(4):216. doi: 10.1007/s00432-024-05649-x. J Cancer Res Clin Oncol. 2024. PMID: 38668936 Free PMC article.
Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
Torasawa M, Yoshida T, Takeyasu Y, Shimoda Y, Tateishi A, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Takahashi K, Ohe Y. Torasawa M, et al. Among authors: masuda k. Cancer Med. 2023 Jun;12(11):12388-12401. doi: 10.1002/cam4.5939. Epub 2023 Apr 16. Cancer Med. 2023. PMID: 37062059 Free PMC article.
Distinct metastatic spread and progression patterns in patients treated with crizotinib for ROS1- and ALK-rearranged non-small cell lung cancer: a single-center retrospective study.
Nakamura T, Yoshida T, Takeyasu Y, Masuda K, Sinno Y, Matsumoto Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Ohe Y. Nakamura T, et al. Among authors: masuda k. Transl Lung Cancer Res. 2023 Jul 31;12(7):1436-1444. doi: 10.21037/tlcr-23-10. Epub 2023 Jun 30. Transl Lung Cancer Res. 2023. PMID: 37577313 Free PMC article.
Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression.
Miyakoshi J, Yoshida T, Kashima J, Shirasawa M, Torasawa M, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Shiraishi K, Kohno T, Yamamoto N, Yatabe Y, Suzuki T, Ohe Y. Miyakoshi J, et al. Among authors: masuda k. Lung Cancer. 2024 May;191:107788. doi: 10.1016/j.lungcan.2024.107788. Epub 2024 Apr 6. Lung Cancer. 2024. PMID: 38593478
2,693 results